Institutional Investors Recalibrate Positions in Manhattan Associates

A significant repositioning is underway among major institutional holders of Manhattan Associates stock. This reshuffling follows the software provider's robust quarterly performance and subsequent upward revision to its annual guidance, revealing a divergence in strategy among heavyweight investment firms.

The trading activity coincides with strong operational results for the third quarter. Manhattan Associates reported earnings that comfortably surpassed market consensus.
* Revenue reached $275.8 million, marking a 3.4% increase year-over-year.
* Earnings Per Share (EPS) came in at $1.36, significantly above the $1.18 analysts had anticipated.

Based on these results, the company's management provided a more precise outlook for the full 2025 fiscal year. The updated forecast now projects EPS in a range of $4.95 to $4.97.

A Surge in Institutional Buying

The most substantial moves have been on the buy side. AQR Capital Management dramatically increased its stake in the second quarter of 2025, boosting its position by 181.6%. The investment giant now holds approximately 1.93 million shares, representing about 3.2% of the company and valued at roughly $380.7 million.

This bullish sentiment is echoed by other major institutions:
* Squarepoint Ops LLC expanded its holdings by 74.7%, accumulating over 322,000 shares.
* AXA S.A. raised its position by 65.2%, bringing its total to 72,807 shares.
* UBS Asset Management reported an increase of 101.7%.

Should investors sell immediately? Or is it worth buying Manhattan?

Collectively, institutional investors now control approximately 98.5% of the company's outstanding shares, with these inflows suggesting confidence in its long-term trajectory.

Contrasting Views Emerge

However, not all asset managers share this outlook, highlighting differing risk assessments at current valuation levels. In a stark contrast to the buying trend, the fund Ossiam drastically reduced its exposure. It sold over 64,000 shares, slashing its holdings by 96.1% to a residual position of just 2,608 shares.

Market Valuation and Analyst Outlook

Manhattan Associates currently commands a market capitalization of around $10.47 billion, with its shares recently trading near the $173 mark.

Market researchers maintain a constructive stance. The consensus price target among analysts stands at $222.42. From the current trading level, this implies substantial potential upside, contingent on the company delivering on its raised annual forecast. The next critical test will be the quarterly results scheduled for January 2026.